Recent developments highlight Cardinal Health's Q1 FY2027 earnings results, raised outlook, specialty growth, and operational updates from earnings calls.

• Cardinal Health reported strong Q1 FY2027 earnings with revenue of $67.513 billion and net income of $554 million for the quarter ending September 30, 2026 [S2].
• The company raised its fiscal year 2027 outlook and highlighted growth in its specialty pharmaceutical segment [N4][N2].
• Q1 earnings and revenues showed strength driven by pharmaceutical demand and specialty growth [N5][N7].
• Cardinal Health boosted its FY26 adjusted EPS outlook reflecting improved earnings expectations [N8].
• The company approved a $5 billion share buyback program as part of its capital allocation strategy [S1].
• Multiple earnings call transcripts and highlights provide detailed operational insights and confirm positive momentum [N1][N3][N6].

The company demonstrates operational strength with significant revenue scale and positive earnings momentum. Recent earnings calls indicate specialty pharmaceutical growth and raised outlooks, suggesting effective execution on growth initiatives. The approval of a $5 billion share buyback program reflects confidence in capital allocation and shareholder returns. Cardinal Health's broad healthcare distribution platform positions it well to capture ongoing demand in pharmaceutical and specialty markets.

Challenges include a current ratio below 1.0, indicating potential liquidity constraints relative to current liabilities. The healthcare distribution industry faces pricing pressures, regulatory risks, and competitive dynamics that could impact margins. Legal and litigation risks, including opioid-related lawsuits, remain a consideration. Execution risks exist around sustaining specialty growth and managing operational costs amid evolving healthcare market conditions.

Cardinal Health's moat is supported by its extensive distribution network, long-standing relationships with major pharmaceutical manufacturers and healthcare providers, and scale advantages in logistics and supply chain management. Its specialty pharmaceutical segment and strategic partnerships contribute to differentiated service offerings that are not easily replicated by smaller competitors.

• Liquidity Risk: The current ratio of 0.88 as of September 30, 2026, suggests that current liabilities exceed current assets, which may pose short-term liquidity challenges.
• Regulatory and Legal Risks: The company faces ongoing legal risks including opioid litigation and regulatory scrutiny that could impact financial results and reputation.
• Competitive and Market Risks: Pricing pressures and competition in pharmaceutical distribution and specialty markets could affect revenue growth and profitability.

• Cardinal Health Inc operates in the healthcare sector with a focus on pharmaceutical and specialty solutions.
• The company reported revenue of $67.513 billion for the quarter ending September 30, 2026, as per the 10-Q filing dated November 5, 2026.
• Net income for the same quarter was $554 million.
• Cash and cash equivalents were $5.264 billion as of September 30, 2026.
• Current assets totaled $40.99 billion and current liabilities were $46.326 billion as of September 30, 2026, resulting in a current ratio of 0.88 and a cash ratio of 0.12.
• The company has recently reported first quarter fiscal year 2027 results and raised its outlook, indicating positive operational momentum [N4].
• Cardinal Health's Q1 earnings and revenues showed strength driven by pharmaceutical demand and specialty growth [N5][N2].
• The company has a history of quarterly earnings calls and transcripts providing detailed operational and financial insights [N1][N3][N6][N7].
• The FY26 adjusted EPS outlook was boosted as per recent updates [N8].
• The company approved a $5 billion buyback program as reported in Q4 2026 earnings coverage [S1].